Table 1. Age specific death rate per thousand per year, number of deaths Department of Public Health and Primary Care, in the 2-year period and the rate ratio (based on England and Wales death rates 1993) in men and women with diabetes. The 95% confidence intervals Charing Cross and Westminster Medi
Screening for thyroid dysfunction in a community population of diabetic patients
β Scribed by Smithson, M.J.
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 39 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0742-3071
No coin nor oath required. For personal study only.
β¦ Synopsis
In a general practice population of 11 300 patients, 223 were known to have diabetes mellitus. Thirteen diabetic patients (5.8 %) had a previous diagnosis of thyroid disease. The study excluded 17 patients who received sole diabetes care at a secondary referral centre (of whom 5 had a previous diagnosis of thyroid disease), 8 with a previous diagnosis of thyroid disease receiving community care, and 1 patient who declined screening. New thyroid disease was diagnosed in 11 patients (8 female, 3 male): 5 with primary hypothyroidism, 4 with subclinical hypothyroidism, 1 with hyperthyroidism and 1 with subclinical hyperthyroidism. Thus the prevalence of undiagnosed thyroid disease in diabetic patients receiving community diabetes care was 5.5 % (9.5 % of female patients), and the prevalence of thyroid disease (previusly known and diagnosed as a result of screening) in the entire population of diabetic patients registered in the general practice was 10.8 %. These findings suggest that screening for thyroid disease should be considered in patients receiving diabetes care in the community.
π SIMILAR VOLUMES
Using a population-based cohort from 10 general practices in East Dorset, the mortality rate of diabetic patients compared to non-diabetic controls was investigated during 8 years follow-up. From a total population of 90660, 917 diabetic patients were identified; 693 (75%) with non-insulin-dependent
The efficacy and safety of oral sildenafil, a potent inhibitor of phosphodiesterase type 5, were evaluated in men with diabetes mellitus and erectile dysfunction (ED). Twenty-one men (aged 42-65 years) were enrolled in a double-blind, placebo-controlled, three-way crossover study conducted in two pa